The FDA and CDC recommended a pause for Ixchiq, a chikungunya vaccine, following reports of adverse events in recipients 60 ...

The European drugs regulator said on Thursday its safety panel has confirmed suicidal thoughts as a side effect of ...

Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin” or the "Company”), a late-stage pharmaceutical company with a broad ...

Cytokinetics' PDUFA date for aficamten was extended to December 26th of 2025, due to the FDA's need to review a submitted ...

Aurobindo Pharma's CuraTeQ Biologics receives marketing authorization for Zefylti filgrastim biosimilar in the UK and EU.

EMERYVILLE, Calif. , May 13, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (NASDAQ: XOMA), the biotech royalty aggregator ...

Key messagesGREG is a five-year, 26.2 million euros initiative that unites 29 partner organisations to advance Real-World ...

On the heels of similar moves in France and the European Union, U.S. health authorities are calling for a pause in the use of ...

Few areas of healthcare are as sensitive as cancer treatment. Each year, around 44,000 cancer tumours are diagnosed here.

Both the FDA and EMA have suspended Ixchiq’s use in older adults after post-marketing serious adverse events that include two ...

Saint Herblain (France), May, 07 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that the European Medicines Agency (EMA) has started a review ...

New research reveals the potential of drugs that have been on the market for decades to treat diseases other than those for ...